SCHEMBL25586502

SCHEMBL25586502

CC(=O)C(C)CCNC(=O)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
ANPEP P15144 1/20 0.38
DNPEP Q9ULA0 1/20 0.38
TSHR P16473 3/20 0.37
USP2 O75604 1/20 0.37
KISS1R Q969F8 1/20 0.36
MEN1 O00255 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPK1 P28482 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA4 P43681 1/20 0.34
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ERCC1 P07992 1/20 0.33
ERCC4 Q92889 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11129 0.79 ANPEP (0.55) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL23467767 0.79 CNR1 (0.49) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL27291249 0.79 TSHR (0.39) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL12131751 0.78 USP2 (0.55) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL20687626 0.77 ALDH1A1 (0.50) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL25608711 0.77 MEN1 (0.52) KMT2ACYP2C9MEN1CHRNB2CHRNB4
SCHEMBL21214691 0.76 KMT2A (0.42) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL21214819 0.76 KMT2A (0.42) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL23788919 0.76 KMT2A (0.42) KMT2ACYP2C19CYP2D6CYP2C9ANPEP
SCHEMBL26857860 0.75 ALDH1A1 (0.39) KMT2AANPEPDNPEPMEN1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165970-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165970-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A KMT2A 4310/4885CYP2C19 3097/4885CYP2D6 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.